Current SDDSs utilize the following strategies to overcome drug resistance, as follows: (1) combining immunogenic cell death (ICD) with cancer immunotherapy; (2) reversing the tumor immunosuppressive microenvironment; (3) regulating IFN and PTEN signaling pathway; and (4) enhancing the efficacy of ACT. The gene discussed is PTEN; the disease is neoplasm.